Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
37
CLPBY Quote, Financials, Valuation and Earnings
Last price:
$8.81
Seasonality move
:
4.56%
Day range:
$8.68 - $8.82
52-week range:
$8.34 - $11.90
Dividend yield:
4%
P/E ratio:
36.94x
P/S ratio:
4.81x
P/B ratio:
8.50x
Volume:
177K
Avg. volume:
408.1K
1-year change:
-19.17%
Market cap:
$19.9B
Revenue:
$4.1B
EPS (TTM):
$0.24
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Coloplast A/S has -- downside to fair value with a price target of -- per share.
CLPBY vs. S&P 500
-
Over the past 5 trading days, Coloplast A/S has overperformed the S&P 500 by 3.5% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Coloplast A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Coloplast A/S has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Coloplast A/S reported revenues of $1.1B.
Earnings Growth
-
Coloplast A/S earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Coloplast A/S reported earnings per share of $0.06.
Enterprise value:
23.3B
EV / Invested capital:
--
Price / LTM sales:
4.81x
EV / EBIT:
20.71x
EV / Revenue:
5.63x
PEG ratio (5yr expected):
13.85x
EV / Free cash flow:
29.95x
Price / Operating cash flow:
25.55x
Enterprise value / EBITDA:
17.37x
Gross Profit (TTM):
$2.8B
Return On Assets:
7.43%
Net Income Margin (TTM):
13.01%
Return On Equity:
21.65%
Return On Invested Capital:
9.13%
Operating Margin:
27.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.5B | $3.9B | $4.1B | $1B | $1.1B | |
| Gross Profit | $2.3B | $2.7B | $2.8B | $683.2M | $745.6M | |
| Operating Income | $974.6M | $1.1B | $1.1B | $289.6M | $300.5M | |
| EBITDA | $1.1B | $1.3B | $1.3B | $339M | $369M | |
| Diluted EPS | $0.32 | $0.33 | $0.24 | $0.09 | $0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.2B | $1.4B | $1.6B | $1.6B | |
| Total Assets | $2.5B | $4.9B | $6.8B | $7.2B | $7.6B | |
| Current Liabilities | $984.1M | $966.5M | $2.3B | $1.5B | $1B | |
| Total Liabilities | $1.2B | $3.8B | $4.4B | $4.5B | $5.1B | |
| Total Equity | $1.3B | $1.1B | $2.5B | $2.7B | $2.5B | |
| Total Debt | $97.6M | $2.2B | $2.5B | $2.6B | $3.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $609.8M | $401.5M | $989.5M | $297.4M | $359.3M | |
| Cash From Investing | -$1.3B | -$193.9M | -$186.3M | -$62.8M | -$62.4M | |
| Cash From Financing | $759.7M | -$220.4M | -$772.4M | -$246.9M | -$262.6M | |
| Free Cash Flow | $430.7M | $206.1M | $777M | $232.8M | $295.9M | |
CLPBY
Sector
Market Cap
$19.9B
$28.3M
Price % of 52-Week High
74.03%
51.99%
Dividend Yield
4%
0%
Shareholder Yield
2.91%
-1.59%
1-Year Price Total Return
-19.17%
-17.41%
Beta (5-Year)
0.917
0.495
Dividend yield:
4%
Annualized payout:
$0.32
Payout ratio:
289.39%
Growth streak:
3 years
Technicals
8-day SMA
Buy
Level
$8.64
200-day SMA
Sell
Level
$9.46
Bollinger Bands (100)
Sell
Level
8.69 - 9.51
Chaikin Money Flow
Buy
Level
888.4K
20-day SMA
Buy
Level
$8.61
Relative Strength Index (RSI14)
Buy
Level
54.44
ADX Line
Buy
Level
17.51
Williams %R
Sell
Level
-2.0833
50-day SMA
Sell
Level
$8.92
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
17.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.9098)
Buy
CA Score
(Annual)
Level (-0.2403)
Buy
Beneish M-Score
(Annual)
Level (-2.7014)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (0.3795)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Voice and Respiratory Care segment refers to the sale of laryngectomy and tracheostomy products. The Interventional Urology segment includes the sale of urological products, including disposable products. The Advanced Wound Dressings segment focuses on the sale of wound and skin care products. The Biologics segment represents a new segment covering the sale of tissue-based products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
Stock Forecast FAQ
In the current month, CLPBY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLPBY average analyst price target in the past 3 months is --.
-
Where Will Coloplast A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Coloplast A/S share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Coloplast A/S?
Analysts are divided on their view about Coloplast A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Coloplast A/S is a Sell and believe this share price will rise from its current level to --.
-
What Is Coloplast A/S's Price Target?
The price target for Coloplast A/S over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLPBY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Coloplast A/S is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CLPBY?
You can purchase shares of Coloplast A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Coloplast A/S shares.
-
What Is The Coloplast A/S Share Price Today?
Coloplast A/S was last trading at $8.81 per share. This represents the most recent stock quote for Coloplast A/S. Yesterday, Coloplast A/S closed at $8.81 per share.
-
How To Buy Coloplast A/S Stock Online?
In order to purchase Coloplast A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CLPBY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLPBY
Sector
P/E ratio
36.94x
24.24x
PEG ratio
13.85x
-0.01x
P/B ratio
8.50x
1.84x
Price / LTM sales
4.81x
1.60x
Growth Metrics
CLPBY
Sector
Revenue growth
6.44%
4.6%
Earnings growth
-29.3%
10.71%
Revenue (5-year growth)
8.2%
6.45%
Earnings forecast
--
-$0.19
Profitability
CLPBY
Sector
Profitability FY 2025
$2.7B
$3.5M
Return on invested capital
9.13%
-32.04%
Return on assets
7.43%
-28.44%
Return on equity
21.65%
-38.09%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
6
Estimated Next Earnings Date
Feb
3
Balance Sheet
CLPBY
Sector
Total cash
$149.1M
$26.1M
Short term investments
--
$25.7M
Total assets
$7.6B
$76.4M
Long term debt
$3.2B
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
